1DD-LSD
Chemical compound related to LSD
| 1DD-LSD | |
|---|---|
|
| |
| Chemical nomenclature | |
| IUPAC name | (6aR,9R)-N,N-diethyl-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide
|
| Identifiers | |
| CAS Number | 123456-78-9 |
| PubChem | 12345678
|
| ChemSpider | 123456 |
| UNII | 123456789A
|
| Chemical data
| |
| Chemical formula | C21H27N3O1
|
| SMILES | CCN(CC)C(=O)[C@@H]1CN(C)[C@H]2c3c1cccc3c4c2[nH]c5c4cccc5
|
1DD-LSD is a psychedelic compound that is structurally related to lysergic acid diethylamide (LSD). It belongs to the class of lysergamides, which are known for their potent effects on the serotonin receptor system in the brain.
Chemical Structure and Properties[edit]

1DD-LSD is a derivative of LSD, with a chemical structure that includes a diethylamide group attached to the lysergic acid moiety. The compound is characterized by the presence of a methyl group at the 7-position of the indole ring, which distinguishes it from other lysergamides. The molecular formula of 1DD-LSD is C21H27N3O, and it has a molar mass of 337.46 g/mol.
Pharmacology[edit]
1DD-LSD acts primarily as an agonist at the 5-HT2A receptor, which is believed to be responsible for its psychedelic effects. Like other lysergamides, it may also interact with other serotonin receptor subtypes, as well as dopamine and norepinephrine receptors, contributing to its complex pharmacological profile.
Effects[edit]
The effects of 1DD-LSD are similar to those of LSD, including alterations in perception, mood, and cognition. Users may experience visual and auditory hallucinations, changes in thought patterns, and an altered sense of time. The intensity and duration of these effects can vary depending on the dose and individual sensitivity.
Legal Status[edit]
The legal status of 1DD-LSD varies by country. In some jurisdictions, it may be classified as a controlled substance due to its structural similarity to LSD and its potential for abuse. In other regions, it may not be specifically scheduled, although it could still be subject to analogue laws.
Synthesis[edit]
The synthesis of 1DD-LSD involves the modification of the lysergic acid backbone, typically starting from ergot alkaloids or synthetic precursors. The process requires advanced knowledge of organic chemistry and access to specialized reagents and equipment.
Related Compounds[edit]
1DD-LSD is part of a broader family of lysergamides, which includes other compounds such as 1P-LSD, ALD-52, and ETH-LAD. These compounds share a common core structure but differ in their side chains, leading to variations in their pharmacological effects and potency.
See Also[edit]
Related Pages[edit]
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian